ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
iShares S&P TSX Canadian Preferred Share Index ETF

iShares S&P TSX Canadian Preferred Share Index ETF (CPD)

12,78
0,01
(0,08%)
Fermé 06 Février 10:12PM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
12,78
Prix Achat
12,73
Prix Vente
12,85
Volume échangé
80 147
12,69 Fourchette du Jour 12,80
0,00 Plage de 52 semaines 0,00
Clôture Veille
12,77
Ouverture
12,69
Dernière Transaction
1200
@
12.78
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

CPD Dernières nouvelles

Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2010

DETROIT, Jan. 28 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) generated net sales of $52.0 million and $178.4 million for the third quarter and first nine...

Caraco Pharmaceutical Laboratories, Ltd. Markets Nicardipine Hydrochloride Injection

DETROIT, Nov. 18 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched Nicardipine Hydrochloride Injection immediately following Sun Pharma's final...

Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Ophthalmic Solution

DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from...

Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Acular(R) Opthalmic Solution

DETROIT, Nov. 6 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) has launched ketorolac tromethamine ophthalmic solution, 0.5% following a final approval from...

/C O R R E C T I O N -- Caraco Pharmaceutical Laboratories, Ltd./

In the news release, Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010, issued 27-Oct-2009 by Caraco Pharmaceutical...

Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2010

DETROIT, Oct. 27 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) generated net sales of $78.4 million and $126.4 million for the second quarter and first six...

Caraco Pharmaceutical Laboratories, Ltd. Closes Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (es

DETROIT, Oct. 2 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that, as part of the previously announced settlement of the legal proceedings...

Caraco Pharmaceutical Laboratories, Ltd. Enters Into Consent Decree with FDA Providing Path to Resume Manufacturing Operations

DETROIT, Sept. 29 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced today that it has entered into a consent decree with the U.S. Food and Drug...

Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation of Georges Ugeux from Board of Directors

DETROIT, Sept. 23 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that on September 20, 2009, Georges Ugeux resigned as a director of the Company...

Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of F. Folsom Bell to Board of Directors

DETROIT, Sept. 15 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced today that the Board appointed F. Folsom Bell to fill the vacancy resulting from...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000SP
40000000SP
120000000SP
260000000SP
520000000SP
1560000000SP
2600000000SP
Aucune Discussion Trouvée
Ajouter une Discussion